Skip to main content

News and Events

Stay up-to-date about
RECOVER

News and Updates

Our understanding of Long COVID is constantly evolving with new research findings. Stay informed by reading the latest news and participating in upcoming events.

129 Results

Filters

129 Results

Filters Applied:

R3 Seminar Recap: Impacts of SARS-CoV-2 on brain, gut, and metabolism

During the December 12th RECOVER Research Review (R3) Seminar, panelists discussed immune features of Long COVID, the relationship between Long COVID and metabolism (chemical reactions that provide the body with energy), and impact of acute and Long COVID on the brain.

R3 Seminar Recap

R3 Seminar Recap: Understanding the role of the immune system in PASC

During the November 14th RECOVER Research Review (R3) Seminar, researchers discussed multiple different biological mechanisms likely underlaid PASC manifestations. This seminar explored several prominent mechanisms that were areas of active study, including persistent SARS-CoV-2 viral reservoirs, abnormal immune system activation, and effects on metabolic pathways.

R3 Seminar Recap

Now Available: Dataset for “Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection”

Authorized researchers may request access to the dataset, which contains more than 3.3 million de-identified data entries and a Data Dictionary.
Observational Adult
Announcement

Changes in the body provide clues for the development of Long COVID

A research team that includes RECOVER researchers found changes in the immune systems of people with Long COVID.
Pathobiology Adult
News Release

RECOVER-NEURO enrolls first participant in trial

RECOVER-NEURO will enroll 315 people and test several different treatments for Long COVID patients who have difficulty focusing, thinking clearly, and remembering things.
Clinical Trial Adult
News Release

NIH launches long COVID clinical trials through RECOVER Initiative, opening enrollment

Initially, RECOVER will test at least four potential treatments for Long COVID, with test of seven more treatments expected in the coming months.

Clinical Trial Adult
News Release

RECOVER-VITAL enrolls first participant in trial

RECOVER-VITAL will enroll 900 people over the next six months and seek to understand whether taking Paxlovid, an antiviral drug, can improve Long COVID symptoms caused by viral persistence.
Clinical Trial Adult
News Release

R3 Seminar Recap: RECOVER in Action: Disparities and Environmental Risk Factors in PASC, EHR Insights

During the July 11th RECOVER Research Review (R3) Seminar, presenters discussed the disparities and environmental risk factors in PASC using EHR Insights. This seminar explored racial and ethnic disparities as well as community-level environmental factors in PASC among adults.

R3 Seminar Recap

Media Inquiries

Are you a member of the media or press? Please direct inquiries to the RECOVER@nih.gov inbox. Please place "MEDIA INQUIRY" in your subject line.

Back to Top